California Health Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California Health Watch.

Press releases published on April 23, 2026

Apr. 23, 2026

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Indeterminate GlobeNewswire

Apr. 23, 2026

Verano Expands Retail Presence on Florida’s Emerald Coast with Opening of MÜV Miramar Beach, the Company’s 85th Florida Dispensary and 162nd Location Nationwide

Indeterminate GlobeNewswire

Apr. 23, 2026

BrewDog USA Doubles Down on Headliners and Ignites Next Wave of Innovation for Spring and Summer

Indeterminate GlobeNewswire

Apr. 23, 2026

Validic Launches Free Developer Tier with API-Driven, Agentic-Ready Self-Signup

Indeterminate GlobeNewswire

Apr. 23, 2026

Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer

Indeterminate GlobeNewswire

Apr. 23, 2026

AAVantgarde to Participate in ARVO 2026, with Presentations at Key Pre-events and New Clinical Data from the LUCE Phase 1/2 Study

Indeterminate GlobeNewswire

Apr. 23, 2026

Aveanna Announces First Quarter 2026 Earnings Release Date and Conference Call

Indeterminate GlobeNewswire

Apr. 23, 2026

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

Indeterminate GlobeNewswire

Apr. 23, 2026

Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer

Indeterminate GlobeNewswire

Apr. 23, 2026

Nectero Therapeutics Reports Two-Year Safety and Efficacy Data from First-in-Human Trial for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms

Indeterminate GlobeNewswire

Apr. 23, 2026

ENA Respiratory Appoints Melissa Faris to Board

Indeterminate GlobeNewswire

Apr. 23, 2026

Epitopea annonce l'approbation de la demande d'essai clinique OVACT pour le CryptiVax-1001 dans le cancer de l'ovaire séreux de haut grade avancé

Indeterminate GlobeNewswire

Apr. 23, 2026

Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)

Indeterminate GlobeNewswire

Apr. 23, 2026

Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours

Indeterminate GlobeNewswire

Apr. 23, 2026

Orion Pharma on aloittanut TEADCO Faasi 1b/2 -tutkimuksen ODM-212-molekyylillä yhdessä vakiintuneiden hoitojen kanssa potilailla, joilla on tiettyjä pitkälle edenneitä kiinteitä kasvaimia

Indeterminate GlobeNewswire

Apr. 23, 2026

OSE Immunotherapeutics annonce la présentation des résultats de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire au Congrès 2026 de l’ASCO

Indeterminate GlobeNewswire

Apr. 23, 2026

Communiqué de presse : T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA

Indeterminate GlobeNewswire

Apr. 23, 2026

OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting

Indeterminate GlobeNewswire

Apr. 23, 2026

Press Release: Q1 2026: double-digit sales and business EPS growth

Indeterminate GlobeNewswire

Apr. 23, 2026

Santhera ernennt Orlando Oliveira zum Chief Executive Officer

Indeterminate GlobeNewswire